Archive for October, 2012

Thomas M. Greene Again Named to Super Lawyers List

Tuesday, October 30th, 2012

In a repeat of last year, Greene LLP Managing Partner Thomas M. Greene was named to the 2012 New England Super Lawyers list.  The distinction is conferred on up to 5% of attorneys, using criteria that include verdicts and settlements, experience, honors and awards, and scholarly lectures and writings.

Greene has been profiled by Super Lawyers in a piece entitled “Unprecedented Success Representing Whistleblowers,” which includes a brief description of the novel theory first used by Greene in Franklin v. Parke-Davis, a False Claims Act case settled in 2004 for a combined $430 million in civil fines and criminal penalties.  Since that time, over $12 billion has been recovered by the government through the use of Greene’s novel off-label promotion theory of recovery.

The Super Lawyers recognition follows a string of other honors and awards for Greene.  After selection as a finalist for the 2011 Public Justice Trial Lawyer of the Year award, Greene received an AV rating by Martindale-Hubbell in which Greene received a 5.0 out of 5.0 in Peer Rating under a new rating system, receiving perfect scores in legal knowledge, analytical capabilities, judgment, communication ability, and legal experience.

Greene LLP Investigating Compounding Pharmacies

Friday, October 19th, 2012

The Boston Globe recently reported that the number of patients who have contracted meningitis has risen to 245, with 19 confirmed deaths.  As many as 14,000 people are at risk of infection from tainted steroid injections from the New England Compounding Center, located in Framingham, Massachusetts.  Meningitis has been found in patients all over the United States, including Tennessee, Michigan, Virginia, Indiana, Maryland, New Jersey, Florida, Ohio, Idaho, Illinois, Minnesota, New Hampshire, North Carolina, Ohio, Pennsylvania, and Texas.

The FDA has not yet made a conclusive determination on how the medications from the Framingham pharmacy became contaminated.  Nonetheless, it has advised facilities and patients that any injectable drug from the New England Compounding Center should not be used if manufactured after May 21 of this year.

Although the NECC is under investigation by health officials and the US Attorney’s Office in Boston, government officials are most likely to pursue criminal remedies against the pharmacy, and are unlikely to fully vindicate the rights of those affected.

Greene LLP has been actively investigating compounding pharmacy practices and procedures for several months in connection with a previously-filed lawsuit unrelated to the NECC, and has recently broadened its investigation to the NECC and similar pharmacies.

Greene LLP is a Boston complex civil litigation firm with extensive experience in pharmaceutical and health care cases.  After a record $430 million in a False Claims Act case against Pfizer in 2004, Greene LLP attorneys have pursued many other pharmaceutical and health care cases under several laws, including state statutes and the federal Racketeering Influenced and Corrupt Organizations Act.  Greene LLP partner Thomas M. Greene has acted as Chairman of the Plaintiffs Steering Committee in a multi-district litigation against Pfizer, winning a $142 million jury verdict in 2010.